FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978930712> ?p ?o ?g. }

• W2978930712 endingPage "637" @default.
• W2978930712 startingPage "627" @default.
• W2978930712 abstract "Despite surgery and adjuvant therapy, early-stage lung adenocarcinoma (LUAD) treatment often fails due to local or metastatic recurrence. However, the mechanism is largely unknown. Here, we report that increased expression levels of miR-134-5p and decreased levels of disabled-2 (DAB2) were significantly correlated with recurrence in stage I LUAD patients. Our data show that miR-134-5p overexpression or DAB2 silencing strongly stimulated LUAD cell metastasis and chemoresistance. In contrast, inhibition of miR-134-5p or overexpression of DAB2 strongly suppressed LUAD cell metastasis and overcame the insensitivity of chemoresistant LUAD cells to chemotherapy. In addition, we demonstrated that DAB2 is a target of miR-134-5p and that miR-134-5p stimulates chemoresistance and metastasis through DAB2 in LUAD. Taken together, these findings suggest that miR-134-5p and its target gene DAB2 have potential as a biomarker for predicting recurrence in stage I LUAD patients. Additionally, miR-134-5p inhibition or DAB2 restoration may be a novel strategy for inhibiting LUAD metastasis and overcoming LUAD cell resistance to chemotherapy. Despite surgery and adjuvant therapy, early-stage lung adenocarcinoma (LUAD) treatment often fails due to local or metastatic recurrence. However, the mechanism is largely unknown. Here, we report that increased expression levels of miR-134-5p and decreased levels of disabled-2 (DAB2) were significantly correlated with recurrence in stage I LUAD patients. Our data show that miR-134-5p overexpression or DAB2 silencing strongly stimulated LUAD cell metastasis and chemoresistance. In contrast, inhibition of miR-134-5p or overexpression of DAB2 strongly suppressed LUAD cell metastasis and overcame the insensitivity of chemoresistant LUAD cells to chemotherapy. In addition, we demonstrated that DAB2 is a target of miR-134-5p and that miR-134-5p stimulates chemoresistance and metastasis through DAB2 in LUAD. Taken together, these findings suggest that miR-134-5p and its target gene DAB2 have potential as a biomarker for predicting recurrence in stage I LUAD patients. Additionally, miR-134-5p inhibition or DAB2 restoration may be a novel strategy for inhibiting LUAD metastasis and overcoming LUAD cell resistance to chemotherapy." @default.
• W2978930712 created "2019-10-10" @default.
• W2978930712 creator A5009714134 @default.
• W2978930712 creator A5029438350 @default.
• W2978930712 creator A5046454314 @default.
• W2978930712 creator A5053780153 @default.
• W2978930712 creator A5066599847 @default.
• W2978930712 date "2019-12-01" @default.
• W2978930712 modified "2023-10-09" @default.
• W2978930712 title "miR-134-5p Promotes Stage I Lung Adenocarcinoma Metastasis and Chemoresistance by Targeting DAB2" @default.
• W2978930712 cites W144423133 @default.
• W2978930712 cites W1648301895 @default.
• W2978930712 cites W1909496986 @default.
• W2978930712 cites W1975529004 @default.
• W2978930712 cites W1989056960 @default.
• W2978930712 cites W2003843680 @default.
• W2978930712 cites W2007138966 @default.
• W2978930712 cites W2010585094 @default.
• W2978930712 cites W2053664200 @default.
• W2978930712 cites W2053934130 @default.
• W2978930712 cites W2079750277 @default.
• W2978930712 cites W2087065324 @default.
• W2978930712 cites W2089082399 @default.
• W2978930712 cites W2092002890 @default.
• W2978930712 cites W2093900801 @default.
• W2978930712 cites W2106671241 @default.
• W2978930712 cites W2114863764 @default.
• W2978930712 cites W2115356925 @default.
• W2978930712 cites W2117317195 @default.
• W2978930712 cites W2121374778 @default.
• W2978930712 cites W2132157071 @default.
• W2978930712 cites W2138885372 @default.
• W2978930712 cites W2147560440 @default.
• W2978930712 cites W2149824100 @default.
• W2978930712 cites W2162674813 @default.
• W2978930712 cites W2175990741 @default.
• W2978930712 cites W2290293600 @default.
• W2978930712 cites W2327474957 @default.
• W2978930712 cites W2335092387 @default.
• W2978930712 cites W2415884819 @default.
• W2978930712 cites W2561895059 @default.
• W2978930712 cites W2588183871 @default.
• W2978930712 cites W2793719304 @default.
• W2978930712 cites W2904554014 @default.
• W2978930712 cites W2911188335 @default.
• W2978930712 cites W2912418493 @default.
• W2978930712 cites W2945379746 @default.
• W2978930712 cites W836654276 @default.
• W2978930712 doi "https://doi.org/10.1016/j.omtn.2019.09.025" @default.
• W2978930712 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6838973" @default.
• W2978930712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31689617" @default.
• W2978930712 hasPublicationYear "2019" @default.
• W2978930712 type Work @default.
• W2978930712 sameAs 2978930712 @default.
• W2978930712 citedByCount "25" @default.
• W2978930712 countsByYear W29789307122020 @default.
• W2978930712 countsByYear W29789307122021 @default.
• W2978930712 countsByYear W29789307122022 @default.
• W2978930712 countsByYear W29789307122023 @default.
• W2978930712 crossrefType "journal-article" @default.
• W2978930712 hasAuthorship W2978930712A5009714134 @default.
• W2978930712 hasAuthorship W2978930712A5029438350 @default.
• W2978930712 hasAuthorship W2978930712A5046454314 @default.
• W2978930712 hasAuthorship W2978930712A5053780153 @default.
• W2978930712 hasAuthorship W2978930712A5066599847 @default.
• W2978930712 hasBestOaLocation W29789307121 @default.
• W2978930712 hasConcept C104317684 @default.
• W2978930712 hasConcept C119056186 @default.
• W2978930712 hasConcept C121608353 @default.
• W2978930712 hasConcept C126322002 @default.
• W2978930712 hasConcept C143998085 @default.
• W2978930712 hasConcept C145059251 @default.
• W2978930712 hasConcept C146357865 @default.
• W2978930712 hasConcept C151730666 @default.
• W2978930712 hasConcept C2776694085 @default.
• W2978930712 hasConcept C2779013556 @default.
• W2978930712 hasConcept C2781182431 @default.
• W2978930712 hasConcept C502942594 @default.
• W2978930712 hasConcept C55493867 @default.
• W2978930712 hasConcept C71924100 @default.
• W2978930712 hasConcept C86803240 @default.
• W2978930712 hasConceptScore W2978930712C104317684 @default.
• W2978930712 hasConceptScore W2978930712C119056186 @default.
• W2978930712 hasConceptScore W2978930712C121608353 @default.
• W2978930712 hasConceptScore W2978930712C126322002 @default.
• W2978930712 hasConceptScore W2978930712C143998085 @default.
• W2978930712 hasConceptScore W2978930712C145059251 @default.
• W2978930712 hasConceptScore W2978930712C146357865 @default.
• W2978930712 hasConceptScore W2978930712C151730666 @default.
• W2978930712 hasConceptScore W2978930712C2776694085 @default.
• W2978930712 hasConceptScore W2978930712C2779013556 @default.
• W2978930712 hasConceptScore W2978930712C2781182431 @default.
• W2978930712 hasConceptScore W2978930712C502942594 @default.
• W2978930712 hasConceptScore W2978930712C55493867 @default.
• W2978930712 hasConceptScore W2978930712C71924100 @default.
• W2978930712 hasConceptScore W2978930712C86803240 @default.
• W2978930712 hasFunder F4320321001 @default.
• W2978930712 hasLocation W29789307121 @default.

• next